Search

everythinglearnresearchcommunity

for

Search:↓

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Thymus-derived Tregs, not peripherally-derived Tregs, primarily regulate type 1 diabetes in the NOD mouse model.

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

γδTregs can protect hair follicles from alopecia areata and may help regrow hair.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Cytokines and neuropeptides are key in controlling androgen levels, affecting skin and hair conditions.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Immune cells are crucial for hair growth and preventing hair loss.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Moderate immune responses help hair growth, while excessive responses slow it down.

RNase L hinders hair follicle regeneration by altering immune signals.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Hair follicle cells help protect against immune attacks by regulating T-cell activity.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.

Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

Type 2 immunity helps control mite growth in hair follicles, preventing damage.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.